Myeloid Cytokines for Treatment of Acute Exposure to Myelosuppressive Doses of Radiation: Hematopoietic Subsyndrome of Acute Radiation Syndrome (H-ARS) - Radiation Emergency Medical Management

Myeloid Cytokines for Treatment of Acute Exposure to Myelosuppressive Doses of Radiation: Hematopoietic Subsyndrome of Acute Radiation Syndrome (H-ARS) - Radiation Emergency Medical Management

Myeloid Cytokines for Treatment of Acute Exposure to
Myelosuppressive Doses of Radiation: Hematopoietic Subsyndrome
of Acute Radiation Syndrome (H-ARS)

 View/Print entire page as PDF (PDF - 53 KB)

Key Clinical Information

• The goals of using a myeloid colony-stimulating factor for radiation-induced myelosuppression are to:
  • Improve survival of adults and children exposed to myelosuppressive doses of radiation
  • Shorten the duration of severe neutropenia
  • Minimize the severity of neutropenia-associated complications, including infection
• Initiation of treatment in a radiation incident should be strongly considered for patients who:
  • Are likely to have received ≥2 gray (Gy) whole body exposure or ≥2 Gy significant partial body exposure
  • Are likely to have an absolute neutrophil count of ≤500 cells/mm3
  • Will likely have prolonged periods of significant neutropenia (See radiation effects on blood counts diagram).
  • Have significant radiation exposure plus trauma and/or burns, which worsens the clinical outcome compared to radiation exposure alone.
• The CDC is responsible for creating and issuing Emergency Use Instructions (EUIs) regarding drug use in emergencies.
  • The EUI authority allows CDC to facilitate the availability of streamlined information about the use of eligible, approved MCMs needed during public health emergencies without FDA needing to issue an Emergency Use Authorization (EUA).